{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-026094","form_type":"8-K","ticker":null,"cik":"0001840904","company_name":"ATAI Life Sciences N.V.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.672399+00:00","generated_at":"2026-06-01T23:32:26.161043+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CEO Florian Brand to step down by YE2024; Dr. Rao to succeed; Q1 net loss $26.7M","bullets":["CEO Florian Brand to step down by Dec 31, 2024; will serve as Co-CEO from June 1 until then.","Co-Founder Dr. Srinivas Rao appointed Co-CEO effective June 1, 2024; to become CEO by YE2024.","Q1 2024 net loss $26.7M ($33.1M in Q1 2023); R&D expenses $11.5M, down from $19.3M YoY.","Cash, equivalents and short-term investments $121.3M at March 31, 2024; sufficient into 2026.","VLS-01 Phase 1b data and BPL-003 Phase 2b TRD topline data both expected in 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-026094","json":"https://secwatch.observer/filing/0001140361-24-026094.json","markdown":"https://secwatch.observer/filing/0001140361-24-026094.md","text":"https://secwatch.observer/filing/0001140361-24-026094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/0001140361-24-026094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/ef20029167_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:32:26.161043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d6faf7ef2dc48d1e841eb78309ca7c745d674a42","claim":"ATAI Life Sciences N.V. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 15, 2024, ATAI Life Sciences N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/0001140361-24-026094-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c85ea5b917","claim":"Srinivas Rao was appointed as Co-Chief Executive Officer at ATAI Life Sciences N.V..","evidence_excerpt":"Effective June 1, 2024, Dr. Srinivas Rao was appointed the Company's Co-Chief Executive Officer and designated as co-principal executive officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/0001140361-24-026094-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Co-Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"dc6c1be4a0","claim":"Florian Brand changed role as Co-Chief Executive Officer at ATAI Life Sciences N.V..","evidence_excerpt":"Mr. Brand will serve as Co-Chief Executive Officer of the Company from June 1, 2024 through December 31, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/0001140361-24-026094-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Role","value":"Co-Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f05cf81232","claim":"Florian Brand departed as Chief Executive Officer at ATAI Life Sciences N.V..","evidence_excerpt":"at which time he will be stepping down from his position as the Company's Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/0001140361-24-026094-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepping down"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}